CGMA CPA - Akebia Ther CFO VP

AKBA Stock  USD 1.92  0.06  3.03%   

CFO

CGMA CPA is CFO VP of Akebia Ther
Age 51
Address 245 First Street, Cambridge, MA, United States, 02142
Phone617 871 2098
Webhttps://www.akebia.com

Akebia Ther Management Efficiency

The company has return on total asset (ROA) of (0.0937) % which means that it has lost $0.0937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5345) %, meaning that it created substantial loss on money invested by shareholders. Akebia Ther's management efficiency ratios could be used to measure how well Akebia Ther manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.78, whereas Return On Tangible Assets are forecasted to decline to (0.37). At present, Akebia Ther's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 182 M, whereas Other Current Assets are forecasted to decline to about 12.6 M.
Akebia Ther currently holds 104.18 M in liabilities with Debt to Equity (D/E) ratio of 2.15, implying the company greatly relies on financing operations through barrowing. Akebia Ther has a current ratio of 1.27, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Akebia Ther's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 6 records

CFO Age

Gurinder MBAOcean Biomedical
58
Marella ThorellSeres Therapeutics
57
Adam MostafaX4 Pharmaceuticals
44
Preetam MBACidara Therapeutics
51
Marella CPASeres Therapeutics
57
PMP CPAElevation Oncology
53
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 426 people. Akebia Ther (AKBA) is traded on NASDAQ Exchange in USA. It is located in 245 First Street, Cambridge, MA, United States, 02142 and employs 167 people. Akebia Ther is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Akebia Ther Leadership Team

Elected by the shareholders, the Akebia Ther's board of directors comprises two types of representatives: Akebia Ther inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akebia. The board's role is to monitor Akebia Ther's management team and ensure that shareholders' interests are well served. Akebia Ther's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akebia Ther's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven Burke, Senior Vice President Chief Medical Officer
Mercedes Carrasco, Director Communications
David Spellman, CFO VP
Tracey Vetterick, Vice Administration
Nicole Hadas, Sr. VP, General Counsel and Secretary
Thierry Bilbault, VP Devel
Kristie Bolieau, VP Controller
Erik MBA, Senior Officer
Michel Dahan, Senior Vice President and Chief Business Officer
Douglas MBA, Vice Strategy
Nicole JD, Chief VP
Nicholas Grund, Senior Officer
Carolyn Rucci, Senior Counsel
Kimberly Garko, Senior Officer
John MBA, President, CEO
Meredith Bowman, Senior Officer
Steven MD, Senior Officer
Richard Malabre, Chief Officer
CGMA CPA, CFO VP
Violetta Cotreau, Chief VP

Akebia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akebia Ther a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Akebia Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akebia Ther's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akebia Ther Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akebia Ther Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.22)
Revenue Per Share
0.834
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.09)
Return On Equity
(5.53)
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.